国际眼科杂志
國際眼科雜誌
국제안과잡지
INTERNATIONAL JOURNAL OF OPHTHALMOLOGY
2014年
6期
1110-1112
,共3页
干眼%治疗%玻璃酸钠%高浓度
榦眼%治療%玻璃痠鈉%高濃度
간안%치료%파리산납%고농도
dry eye%therapy%sodium hyaluronate%high concentration
目的：观察高浓度玻璃酸钠滴眼液治疗中重度干眼的临床疗效。<br> 方法：中重度干眼患者40例随机分成试验组和对照组,每组各20例。试验组用玻璃酸钠滴眼液(3g/L)、对照组玻璃酸钠滴眼液(1g/L)联合重组人表皮生长因子滴眼液治疗,治疗前和治疗2 wk后,通过症状评分、眼表疾病指数( OSDI)评分、泪膜破裂时间( BUT )、泪液分泌试验(Schirmer I test,SIt)、角膜荧光素染色评分(FL)等评价两组疗效。<br> 结果：治疗前,两组各项指标差异均无统计学意义。治疗2 wk后,除SIt外,两组的其他指标和治疗前相比,差异均有统计学意义；两组间相比,除症状评分和OSDI差异有统计学意义,余无统计学差异。<br> 结论：高浓度玻璃酸钠滴眼液治疗中重度干眼,能有效缓解眼部不适症状,提高患者生存质量。
目的：觀察高濃度玻璃痠鈉滴眼液治療中重度榦眼的臨床療效。<br> 方法：中重度榦眼患者40例隨機分成試驗組和對照組,每組各20例。試驗組用玻璃痠鈉滴眼液(3g/L)、對照組玻璃痠鈉滴眼液(1g/L)聯閤重組人錶皮生長因子滴眼液治療,治療前和治療2 wk後,通過癥狀評分、眼錶疾病指數( OSDI)評分、淚膜破裂時間( BUT )、淚液分泌試驗(Schirmer I test,SIt)、角膜熒光素染色評分(FL)等評價兩組療效。<br> 結果：治療前,兩組各項指標差異均無統計學意義。治療2 wk後,除SIt外,兩組的其他指標和治療前相比,差異均有統計學意義；兩組間相比,除癥狀評分和OSDI差異有統計學意義,餘無統計學差異。<br> 結論：高濃度玻璃痠鈉滴眼液治療中重度榦眼,能有效緩解眼部不適癥狀,提高患者生存質量。
목적：관찰고농도파리산납적안액치료중중도간안적림상료효。<br> 방법：중중도간안환자40례수궤분성시험조화대조조,매조각20례。시험조용파리산납적안액(3g/L)、대조조파리산납적안액(1g/L)연합중조인표피생장인자적안액치료,치료전화치료2 wk후,통과증상평분、안표질병지수( OSDI)평분、루막파렬시간( BUT )、루액분비시험(Schirmer I test,SIt)、각막형광소염색평분(FL)등평개량조료효。<br> 결과：치료전,량조각항지표차이균무통계학의의。치료2 wk후,제SIt외,량조적기타지표화치료전상비,차이균유통계학의의；량조간상비,제증상평분화OSDI차이유통계학의의,여무통계학차이。<br> 결론：고농도파리산납적안액치료중중도간안,능유효완해안부불괄증상,제고환자생존질량。
AIM: To observe the efficacy of high concentrations of sodium hyaluronate ( 3g/L SH ) for moderate to severe dry eye. <br> METHODS: Forty moderate to severe dry eye patients were included in the study according to the diagnosis criteria and randomized into two groups. The patients of the trial group received topical administration of high concentration sodium hyaluronate (3g/L), and those of the control group received sodium hyaluronate ( 1g/L ) plus recombinant human epidermal growth factor. The dry eye symptom scores, ocular surface disease index ( OSDI) scores, tear film break-up time ( BUT) , SchirmerⅠ test and corneal fluorescein staining score were evaluated. All the indexes were compared between the two groups 2wk before and after treatment. <br> RESULTS: There were no significant differences of the indicators between the two groups before treatment. After 2wk treatment, the differences were statistically significant compared to former except for the SchirmerⅠtest. Compared with the control group, the symptom scores and the OSDI scores were lowered. No significant differences were found in the other indicators between these two groups. <br> CONCLUSION: Topical usage of highconcentrations of sodium hyaluronate (3g/L) is beneficial for remitting the ocular symptoms in moderate to severe dry eyes, and also improve the quality of life of patients.
